Studie k posouzení nežádoucích příhod, změn v aktivitě onemocnění a toho, jak intravenózní a subkutánní risankizumab prochází tělem pediatrických účastníků se středně těžkou až těžkou aktivní Crohnovou chorobou (RISE)
Multicentrická studie fáze 3 k vyhodnocení farmakokinetiky, účinnosti a bezpečnosti risankizumabu s otevřenou indukcí, randomizovanou dvojitě zaslepenou údržbou a dlouhodobým prodloužením období u pediatrických subjektů (ve věku 2 až < 18 let) s Středně až těžce aktivní Crohnova choroba
Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess the pharmacokinetics, efficacy, and safety of risankizumab in pediatric participants with moderately to severely active CD aged 2 to < 18 years old who have had intolerance or inadequate response to other therapies.
Risankizumab is an approved drug for adults with plaque psoriasis, psoriatic arthritis, and CD and is being developed for the treatment of CD in pediatrics. This study is comprised of 3 cohorts that may participate in 3 substudies (SS). Cohort 1 will enroll participants with ages from 6 to less than 18 years. Cohort 2 will enroll participants with ages from 2 to less than 6 years. Cohort 3 will enroll participants with ages from 2 to less than 18 years. SS1 is an open-label induction period where participants will receive a weight-based induction regimen of risankizumab. SS2 is a double-blind maintenance period where participants will be randomized to receive 1 of 2 doses of weight-based induction regimen of risankizumab. SS3 is an open-label extension period where participants will receive risankizumab based off of their response in SS2. Approximately 110 pediatric participants with CD will be enrolled at around 100 sites worldwide.
Participants in SS1 will receive risankizumab intravenously during the 12-week induction period. Participants in SS2 will receive risankizumab subcutaneously during the 52-week randomized maintenance period. Participants in SS3 will receive risankizumab subcutaneously during the 208-week open label period. Participants will be followed-up for approximately 140 days.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Typ studie
Typ studie
Zápis (Odhadovaný)
Zápis
Fáze
Fáze
- Fáze 3
Kontakty a umístění
Studijní kontakt
Studijní kontakt
- Jméno: ABBVIE CALL CENTER
- Telefonní číslo: 844-663-3742
- E-mail: abbvieclinicaltrials@abbvie.com
Studijní místa
-
-
-
Brussels, Belgie, 1020
- Nábor
- Hospital Universite Enfants Reine Fabiola /ID# 255112
-
Liège, Belgie, 4000
- Nábor
- Groupe Sante CHC - Clinique du MontLegia /ID# 255620
-
-
Antwerpen
-
Edegem, Antwerpen, Belgie, 2650
- Nábor
- Uza /Id# 255114
-
-
Brussels Capital
-
Brussels, Brussels Capital, Belgie, 1200
- Nábor
- Cliniques Universitaires UCL Saint-Luc /ID# 255108
-
Jette, Brussels Capital, Belgie, 1090
- Nábor
- Universitair Ziekenhuis Brussel /ID# 255109
-
-
Vlaams-Brabant
-
Leuven, Vlaams-Brabant, Belgie, 3000
- Nábor
- Universitair Ziekenhuis Leuven /ID# 255098
-
-
-
-
-
Plovdiv, Bulharsko, 4002
- Nábor
- UMHAT Sveti Georgi EAD /ID# 255386
-
Sofia, Bulharsko, 1606
- Dokončeno
- Specialized Hospital For Active Treatment Of Children Diseases Prof. Ivan Mitev /ID# 255384
-
Varna, Bulharsko, 9009
- Nábor
- UMHAT Multiprofile Hospital for Active Treatment Sveta Marina /ID# 256358
-
-
-
-
-
Paris, Francie, 75015
- Nábor
- AP-HP - Hopital Necker /ID# 255608
-
-
Centre-Val de Loire
-
Tours, Centre-Val de Loire, Francie, 37044
- Nábor
- CHRU Tours - Hopital Gatien de Clocheville /ID# 255052
-
-
New Aquitaine
-
Bordeaux, New Aquitaine, Francie, 33076
- Nábor
- Chu Bordeaux - Hopital Pellegrin /ID# 257060
-
-
Occitanie
-
Toulouse, Occitanie, Francie, 31059
- Nábor
- CHU Toulouse - Hopital Paule de Viguier /ID# 255609
-
-
Rhone
-
Bron, Rhone, Francie, 69500
- Nábor
- Hospices Civils de Lyon - Hopital Femme Mere Enfant /ID# 255443
-
-
-
-
North Holland
-
Amsterdam, North Holland, Holandsko, 1105 AZ
- Nábor
- Amsterdam University Medical Center /ID# 254827
-
-
-
-
-
Messina, Itálie, 98125
- Nábor
- Azienda Ospedaliera Universitaria Gaetano Martino /ID# 255044
-
-
Genova
-
Genoa, Genova, Itálie, 16147
- Nábor
- IRCCS Istituto Giannina Gaslini /ID# 255262
-
-
Napoli
-
Naples, Napoli, Itálie, 80131
- Nábor
- Azienda Ospedaliera Universitaria Federico II - Naples /ID# 255045
-
-
Roma
-
Rome, Roma, Itálie, 00165
- Nábor
- Ospedale Pediatrico Bambino Gesu /ID# 255043
-
-
-
-
Central District
-
Petah Tikva, Central District, Izrael, 4920235
- Nábor
- Schneider Children's Medical Center /ID# 254950
-
-
Jerusalem
-
Jerusalem, Jerusalem, Izrael, 91031
- Nábor
- Shaare Zedek Medical Center /ID# 254951
-
-
-
-
Aichi-ken
-
Ōbu, Aichi-ken, Japonsko, 474-8710
- Nábor
- Aichi Children's Health And Medical Center /ID# 272085
-
-
Chiba
-
Kashiwa-shi, Chiba, Japonsko, 277-0871
- Nábor
- Tsujinaka Hospital - Kashiwanoha /ID# 268409
-
-
Fukuoka
-
Kurume-shi, Fukuoka, Japonsko, 830-0011
- Nábor
- Kurume University Hospital /ID# 268418
-
-
Gunma
-
Maebashi, Gunma, Japonsko, 371-8511
- Nábor
- Gunma University Hospital /ID# 270560
-
-
Kumamoto
-
Kumamoto, Kumamoto, Japonsko, 861-8520
- Nábor
- Japanese Red Cross Kumamoto Hospital /ID# 268586
-
-
Osaka
-
Izumi-Shi, Osaka, Japonsko, 594-1101
- Nábor
- Osaka Women's and Children's Hospital /ID# 268419
-
-
Saitama
-
Saitama-shi, Saitama, Japonsko, 330-8777
- Nábor
- Saitama Children's Medical Center /ID# 268410
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Japonsko, 113-8519
- Nábor
- Institute of Science Tokyo Hospital /ID# 269175
-
Fuchu-shi, Tokyo, Japonsko, 183-8561
- Nábor
- Tokyo Metropolitan Children's Medical Center /ID# 268415
-
Setagaya City, Tokyo, Japonsko, 157-8535
- Nábor
- National Center For Child Health And Development /ID# 268420
-
-
-
-
-
Daegu, Jižní Korea, 41404
- Nábor
- Kyungpook National University Chilgok Hospital /ID# 255817
-
-
Seoul Teugbyeolsi
-
Seoul, Seoul Teugbyeolsi, Jižní Korea, 03080
- Nábor
- Seoul National University Hospital /ID# 255318
-
Seoul, Seoul Teugbyeolsi, Jižní Korea, 06351
- Nábor
- Samsung Medical Center /ID# 255284
-
Seoul, Seoul Teugbyeolsi, Jižní Korea, 03722
- Nábor
- Yonsei University Health System - Severance Hospital /ID# 256976
-
-
-
-
Alberta
-
Calgary, Alberta, Kanada, T3B 6A8
- Nábor
- Alberta Children's Hospital /ID# 255357
-
Edmonton, Alberta, Kanada, T6G 1C9
- Nábor
- Edmonton Clinic Health Academy /ID# 255361
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V6H 3V4
- Nábor
- BC Children's Hospital /ID# 255359
-
-
Ontario
-
London, Ontario, Kanada, N6A 5W9
- Nábor
- London Health Sciences Centre - Victoria Hospital & Children's Hospital /ID# 258598
-
-
-
-
Bavaria
-
Munich, Bavaria, Německo, 80337
- Nábor
- Dr. von Haunerschen Kinderspital /ID# 255577
-
-
North Rhine-Westphalia
-
Münster, North Rhine-Westphalia, Německo, 48149
- Nábor
- Universitaetsklinikum Muenster /ID# 256762
-
-
-
-
Kuyavian-Pomeranian Voivodeship
-
Torun, Kuyavian-Pomeranian Voivodeship, Polsko, 87-100
- Dokončeno
- Gastromed Sp. z o.o /ID# 255939
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Polsko, 04-730
- Nábor
- Instytut Pomnik - Centrum Zdrowia Dziecka /ID# 255938
-
-
-
-
-
Dorado, Portoriko, 00646
- Nábor
- Puerto Rico Health Institute /ID# 255071
-
San Juan, Portoriko, 00909-1711
- Nábor
- Clinical Research Puerto Rico /ID# 266479
-
-
-
-
-
Birmingham, Spojené království, B4 6NH
- Nábor
- Birmingham Women's and Children's NHS Foundation Trust /ID# 255759
-
-
England
-
Sheffield, England, Spojené království, S10 2TH
- Nábor
- Sheffield Children's Hospital NHS Foundation Trust /ID# 255758
-
Kontakt:
- Site Coordinator
- Telefonní číslo: +44 114 273 0522
-
-
Greater London
-
London, Greater London, Spojené království, E1 2ES
- Nábor
- Disc_Barts Health NHS Trust - The Royal London Hospital /ID# 255757
-
-
-
-
Arizona
-
Phoenix, Arizona, Spojené státy, 85016-7710
- Nábor
- Phoenix Children's Hospital /ID# 255766
-
-
Arkansas
-
Little Rock, Arkansas, Spojené státy, 72202
- Dokončeno
- Arkansas Children's Hospital /ID# 255762
-
-
California
-
Oakland, California, Spojené státy, 94609
- Nábor
- UCSF Benioff Children's Hospital - Oakland /ID# 258327
-
-
Colorado
-
Aurora, Colorado, Spojené státy, 80045
- Nábor
- Children's Hospital Colorado - Aurora /ID# 255764
-
-
Florida
-
Orlando, Florida, Spojené státy, 32806-1141
- Nábor
- Arnold Palmer Hospital for Children Center Digestive Health and Nutrition-Orland /ID# 255437
-
-
Indiana
-
Indianapolis, Indiana, Spojené státy, 46202
- Nábor
- Indiana University Health Riley Hospital for Children /ID# 256454
-
-
Massachusetts
-
Waltham, Massachusetts, Spojené státy, 02451
- Nábor
- Massachusetts General Hospital - Mass General Waltham /ID# 255767
-
-
Minnesota
-
Minneapolis, Minnesota, Spojené státy, 55413-2195
- Nábor
- MNGI Digestive Health, P. A. /ID# 255366
-
-
New Jersey
-
Morristown, New Jersey, Spojené státy, 07960
- Nábor
- Goryeb Childrens Hospital /ID# 256452
-
-
New York
-
New York, New York, Spojené státy, 10029
- Nábor
- Icahn School of Medicine at Mount Sinai /ID# 254880
-
-
Ohio
-
Cleveland, Ohio, Spojené státy, 44195
- Nábor
- Cleveland Clinic - Cleveland /ID# 256453
-
Kontakt:
- Site Coordinator
- Telefonní číslo: 216-636-2007
-
-
-
-
-
Changhua City, Changhua County, Tchaj-wan, 50006
- Nábor
- Changhua Christian Hospital /ID# 256082
-
Taipei, Tchaj-wan, 100
- Nábor
- National Taiwan University Hospital /ID# 255679
-
-
-
-
-
Ankara, Turecko (Türkiye), 06560
- Nábor
- Gazi University Medical Faculty /ID# 255086
-
Istanbul, Turecko (Türkiye), 34453
- Nábor
- Sariyer Hamidiye Etfal Egitim Ve Araştirma Hastanesi /ID# 257143
-
Istanbul, Turecko (Türkiye), 34899
- Nábor
- Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi /ID# 261020
-
Kocaeli, Turecko (Türkiye), 41380
- Nábor
- Kocaeli University Med Faculty /ID# 256922
-
-
-
-
Praha 17
-
Prague, Praha 17, Česko, 128 00
- Dokončeno
- Vseobecna Fakultni nemocnice v Praze /ID# 256096
-
-
Praha 5
-
Prague, Praha 5, Česko, 150 06
- Dokončeno
- Fakultni nemocnice Motol a Homolka /ID# 256547
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Čína, 100045
- Nábor
- Beijing Children's Hospital /ID# 256081
-
Beijing, Beijing Municipality, Čína, 100191
- Nábor
- Peking University Third Hospital /ID# 255876
-
Kontakt:
- Site Coordinator
- Telefonní číslo: +86 010-82266699
-
-
Guangdong
-
Guangzhou, Guangdong, Čína, 510620
- Nábor
- Guangzhou Medical University Affiliated Women and Children's Medical Center /ID# 255428
-
Guangzhou, Guangdong, Čína, 510655
- Nábor
- The Sixth Affiliated Hospital of Sun Yat-sen University /ID# 270589
-
-
Henan
-
Zhengzhou, Henan, Čína, 450018
- Nábor
- Henan Children's Hospital Zhengzhou Children's Hospital /ID# 255562
-
-
Hunan
-
Changsha, Hunan, Čína, 410007
- Nábor
- Hunan Children's Hospital /ID# 255610
-
-
Jiangxi
-
Nanchang, Jiangxi, Čína, 330006
- Nábor
- Jiangxi Provincial Children's Hospital /ID# 255564
-
-
Liaoning
-
Shenyang, Liaoning, Čína, 110022
- Nábor
- Shengjing Hospital of China Medical University /ID# 255563
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Čína, 200062
- Nábor
- Children's Hospital of Shanghai /ID# 255531
-
Shanghai, Shanghai Municipality, Čína, 200065
- Nábor
- Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 255688
-
-
-
-
-
Madrid, Španělsko, 28009
- Dokončeno
- Hospital Infantil Universitario Nino Jesus /ID# 255012
-
Málaga, Španělsko, 29011
- Nábor
- Hospital Regional Universitario de Malaga /ID# 257553
-
-
A Coruna
-
Ferrol, A Coruna, Španělsko, 15405
- Nábor
- Hospital Arquitecto Marcide - Complejo Hospitalario Universitario de Ferrol /ID# 255614
-
-
-
-
Stockholm County
-
Stockholm, Stockholm County, Švédsko, 118 83
- Nábor
- Sodersjukhuset /ID# 255239
-
Stockholm, Stockholm County, Švédsko, 171 76
- Nábor
- Astrid Lindgrens Barnsjukhus /ID# 255240
-
-
Västra Götaland County
-
Gothenburg, Västra Götaland County, Švédsko, 413 46
- Nábor
- Sahlgrenska Universitetssjukhuset /ID# 255236
-
Kontakt:
- Site Coordinator
- Telefonní číslo: +46313435865
-
-
-
-
-
Bern, Švýcarsko, 3010
- Nábor
- Inselspital, Universitaetsspital Bern /ID# 255321
-
-
Canton of Zurich
-
Zurich, Canton of Zurich, Švýcarsko, 8032
- Nábor
- Kinderspital Zurich - Eleonorenstiftung /ID# 255337
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Pediatric individuals, 2 to < 18 years old
- Must have moderately to severely active CD, as defined by the PCDAI score > 30 assessed at Baseline
- Must have endoscopic evidence of mucosal inflammation as documented by the SES-CD of ≥ 6 for ileocolonic or colonic disease (or SES-CD of ≥ 4 for isolated ileal disease)
- Demonstrated intolerance or inadequate response to one or more of the following categories of drugs: aminosalicylates (This drug class is not sufficient for eligibility for subjects in France, Italy, Netherlands, Spain, and Sweden), oral locally acting corticosteroids, systemic steroids (prednisone or equivalent), IMMs, and/or biologic therapies
Exclusion Criteria:
-
History of hereditary fructose intolerance (a rare genetic condition) or an allergic reaction or significant sensitivity to constituents of the study drug (and its excipients) and/or other products in the same class
-
Any of the following medical disorders:
-
Current diagnosis of ulcerative colitis, indeterminate colitis, or monogenic IBD.
-
A diagnosis of CD prior to 2 years of age.
-
A diagnosis or suspected diagnosis of a primary immunodeficiency.
-
Currently known complications of CD such as:
- Active abscess (abdominal or perianal);
- Symptomatic bowel strictures;
- > 2 missing segments of the following 5 segments: terminal ileum, right colon, transverse colon, sigmoid and left colon, and rectum;
- Fulminant colitis;
- Toxic megacolon;
- Or any other manifestation that might require surgery while enrolled in the study.
-
Ostomy or ileoanal pouch.
-
Diagnosis of short gut or short bowel syndrome.
-
Surgical bowel resection within the past 3 months prior to Baseline (excluding gastrointestinal surgeries which are not bowel resections such as appendectomy or ostomy closure), or a history of >3 bowel resections.
-
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Sekvenční přiřazení
- Maskování: Čtyřnásobek
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: PK Cohort 1: SS3 Dose A
Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Intravenous (IV) Infusion
Ostatní jména:
Subcutaneous (SC) Injection
Ostatní jména:
|
|
Experimentální: PK Cohort 1: SS3 Dose B
Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Intravenous (IV) Infusion
Ostatní jména:
Subcutaneous (SC) Injection
Ostatní jména:
|
|
Experimentální: PK Cohort 2: SS1
Cohort 2 will enroll participants aged 2 to less than 6 years. SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All subjects who complete SS1 are eligible to enter SS2. |
Intravenous (IV) Infusion
Ostatní jména:
Subcutaneous (SC) Injection
Ostatní jména:
|
|
Experimentální: PK Cohort 2: SS3 Dose A
Cohort 2 will enroll participants aged 2 to less than 6 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Intravenous (IV) Infusion
Ostatní jména:
Subcutaneous (SC) Injection
Ostatní jména:
|
|
Experimentální: PK Cohort 2: SS3 Dose B
Cohort 2 will enroll participants aged 2 to less than 6 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Intravenous (IV) Infusion
Ostatní jména:
Subcutaneous (SC) Injection
Ostatní jména:
|
|
Experimentální: Expansion Cohort 3: SS3 Dose A
Cohort 3 will enroll participants aged 2 to less than 18 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Intravenous (IV) Infusion
Ostatní jména:
Subcutaneous (SC) Injection
Ostatní jména:
|
|
Experimentální: Expansion Cohort 3: SS3 Dose B
Cohort 3 will enroll participants aged 2 to less than 18 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Intravenous (IV) Infusion
Ostatní jména:
Subcutaneous (SC) Injection
Ostatní jména:
|
|
Experimentální: PK Cohort 1: SS1
Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All participants who complete SS1 are eligible to enter SS2. |
Intravenous (IV) Infusion
Ostatní jména:
Subcutaneous (SC) Injection
Ostatní jména:
|
|
Experimentální: PK Cohort 1: SS2 Dose A
Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
Intravenous (IV) Infusion
Ostatní jména:
Subcutaneous (SC) Injection
Ostatní jména:
|
|
Experimentální: PK Cohort 1: SS2 Dose B
Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
Intravenous (IV) Infusion
Ostatní jména:
Subcutaneous (SC) Injection
Ostatní jména:
|
|
Experimentální: PK Cohort 2: SS2 Dose A
Cohort 2 will enroll participants aged 2 to less than 6 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
Intravenous (IV) Infusion
Ostatní jména:
Subcutaneous (SC) Injection
Ostatní jména:
|
|
Experimentální: PK Cohort 2: SS2 Dose B
Cohort 2 will enroll participants aged 2 to less than 6 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
Intravenous (IV) Infusion
Ostatní jména:
Subcutaneous (SC) Injection
Ostatní jména:
|
|
Experimentální: Expansion Cohort 3: SS1
Cohort 3 will enroll participants aged 2 to less than 18 years. SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All subjects who complete SS1 are eligible to enter SS2. |
Intravenous (IV) Infusion
Ostatní jména:
Subcutaneous (SC) Injection
Ostatní jména:
|
|
Experimentální: Expansion Cohort 3: SS2 Dose A
Cohort 3 will enroll participants aged 2 to less than 18 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive either double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
Intravenous (IV) Infusion
Ostatní jména:
Subcutaneous (SC) Injection
Ostatní jména:
|
|
Experimentální: Expansion Cohort 3: SS2 Dose B
Cohort 3 will enroll participants aged 2 to less than 18 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive either double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
Intravenous (IV) Infusion
Ostatní jména:
Subcutaneous (SC) Injection
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Cohort 3 (Substudy 2): Percentage of Participants Achieving Pediatric Crohn's Disease Activity Index (PCDAI) Clinical Remission
Časové okno: At 64 weeks
|
PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10. |
At 64 weeks
|
|
Cohort 3 (Substudy 2): Percentage of Participants Achieving Endoscopic Response per Simple Endoscopic Score for Crohn's Disease (SES-CD)
Časové okno: At 64 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline). |
At 64 weeks
|
|
Cohorts 1 & 2: Maximum Observed Serum Concentration (Cmax) of Risankizumab
Časové okno: Up to approximately Week 64
|
Cmax of risankizumab |
Up to approximately Week 64
|
|
Cohorts 1 & 2: Time to Cmax (Tmax) of Risankizumab
Časové okno: Up to approximately 64 weeks
|
Tmax of risankizumab |
Up to approximately 64 weeks
|
|
Cohorts 1 & 2: Area Under the Serum Concentration-Time Curve Over the Dosing Interval (AUCtau) of Risankizumab
Časové okno: Up to approximately 64 weeks
|
AUCtau of risankizumab |
Up to approximately 64 weeks
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Cohort 3 (Substudy 1): Percentage of Participants Achieving PCDAI Clinical Remission
Časové okno: At 12 weeks
|
PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10. |
At 12 weeks
|
|
Cohort 3 (Substudy 1): Percentage of Participants Achieving Endoscopic Response per SES-CD
Časové okno: At 12 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline). |
At 12 weeks
|
|
Cohort 3 (Substudy 1): Percentage of Participants Achieving Endoscopic Remission per SES-CD
Časové okno: At 12 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader. |
At 12 weeks
|
|
Cohort 3 (Substudy 2): Percentage of Participants Achieving Endoscopic Remission per SES-CD
Časové okno: At 64 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader. |
At 64 weeks
|
|
Cohort 3 (Substudy 2): Percentage of Participants Achieving Corticosteroid-Free Clinical Remission per PCDAI
Časové okno: At 64 weeks
|
PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. PCDAI corticosteroid-free remission was defined as discontinued corticosteroid use at least 90 consecutive days prior to the respective visit, with a PCDAI ≤ 10 at that visit. |
At 64 weeks
|
|
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving PCDAI Clinical Remission
Časové okno: At 64 weeks
|
PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10. |
At 64 weeks
|
|
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving Endoscopic Response per SES-CD
Časové okno: At 64 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline). |
At 64 weeks
|
|
Cohorts 1 & 2 (Substudy 1): Percentage of Participants Achieving PCDAI Clinical Remission
Časové okno: At 12 weeks
|
PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10. |
At 12 weeks
|
|
Cohorts 1 & 2 (Substudy 1): Percentage of Participants Achieving Endoscopic Response per SES-CD
Časové okno: At 12 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline). |
At 12 weeks
|
|
Cohorts 1 & 2 (Substudy 1): Percentage of Participants Achieving Endoscopic Remission per SES-CD
Časové okno: At 12 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader. |
At 12 weeks
|
|
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving Endoscopic Remission per SES-CD
Časové okno: At 64 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader. |
At 64 weeks
|
|
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving Corticosteroid-Free Clinical Remission per PCDAI
Časové okno: At 64 weeks
|
PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. PCDAI corticosteroid-free remission was defined as discontinued corticosteroid use at least 90 consecutive days prior to the respective visit, with a PCDAI ≤ 10 at that visit. |
At 64 weeks
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Vyšetřovatelé
Vyšetřovatelé
- Ředitel studie: ABBVIE INC., AbbVie
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
Další identifikační čísla studie
- M16-194
- 2022-502050-14-00 (Jiný identifikátor: EU CT)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Časový rámec sdílení IPD
For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Kritéria přístupu pro sdílení IPD
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Typ podpůrných informací pro sdílení IPD
- PROTOKOL STUDY
- MÍZA
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
produkt vyrobený a vyvážený z USA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .